Mindfulness in Endometrial and Cervical Cancer
NCT04512144
Cervical Cancer, Endometrial Cancer
St Louis, Missouri, United States
View Trial DetailsNCT Number: NCT04475354
Rationale: A growing number of cervical cancer patients live years beyond their cancer diagnosis and ultimately survive their disease. Cervical cancer patients report higher levels of psychological distress compared to other (gynecological) cancer types, resulting in physical and psychosocial limitations. The mechanisms explaining why some patients do, and others do not experience persistent psychological distress after cervical cancer remain unclear.
Objective: Gain insight into the mechanisms explaining psychological distress (i.e. anxiety, depression, cancer worry, perceived stress) in a prospective population-based sample of cervical cancer patients. Factors to be studied include characteristics of the individual (demographical and clinical, including comorbidities), characteristics of the environment ((sexual) relationships), biological function (cortisol, melatonin and sex hormone production assessed in scalp hair, inflammation and telomere length assessed in blood, overall quality of life (EORTC QLQ-C30), symptoms (EORTC QLQ-CX24), functional status (physical activity and sleep measured using the Actigraph activity tracker, and food intake measured using the online 'Eetmeter'), and general health perceptions (B-IPQ). The second aim is to assess the impact of cervical cancer on partners' distress (cancer worry, illness perceptions, relationship quality, dyadic coping).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Amphia, Breda, Netherlands
Study design: Prospective population-based study in which cervical cancer patients and their partners are included shortly after diagnosis and followed until 10 years after diagnosis. Patients from treatment centres in the Netherlands and their partners will be asked to complete questionnaires after diagnosis, after 6 months, and after 1, 2, 5 and 10 year. Clinical data like disease stage, initial treatment and mortality will be extracted from the Netherlands Cancer Registry. In a subsample of patients, additionally objective lifestyle (actigraph, biosensor) and biological (blood, hair) measures are assessed at diagnosis and after 6, 12 and 24 months. .
Study population: Newly diagnosed stage 1-3 cervical cancer patients (N=520) and their partners (N=312, expected) from any treatment centre in the Netherlands will be asked to fill out questionnaires. In a subsample of patients (N=116) additionally lifestyle and biological measures are assessed at all time-points.
Main study parameters/endpoints: psychological distress (anxiety, depression, perceived stress, cancer worry)
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients and partners are asked to complete a questionnaire at 6 points in time: after diagnosis, after 6 months, and after 1, 2, 5 and 10 year. Patients will additionally be asked to complete an online food diary for 3 days. A subsample of patients will be asked to donate blood samples (2X10 ml, 10 minutes) to assess inflammation markers and telomere length, to donate a scalp hair sample (10 mg) to assess hormone production after diagnosis and after 6, 12 and 24 months, and to wear an Actigraph activity tracker to assess physical activity and sleep and a Philips Biosensor to assess heart rate variability as a marker of vagal nerve function at 6, 12 and 24 months.
Only the study team can determine whether someone qualifies for participation.
Patients
Inclusion criteria
Exclusion criteria
Partners
Inclusion criteria
Exclusion criteria
Time frame: 24 months
Hospital Anxiety and Depression Scale (1-21, higher scores indicate more anxiety or depression)
Time frame: 24 months
Impact of Cancer version 2 (Worry Scale) (0-5, higher scores indicate more worry)
Time frame: 24 months
Perceived Stress Scale (0-40, higher scores indicate more perceived stress)
Time frame: 24 months
EORTC Quality of Life Questionnaire (QLQC30) (0-100, higher scores indicate better quality of life or more symptoms)
Time frame: 24 months
EORTC Cervical Cancer Module (CX24) (0-100, higher scores indicate better quality of life or more symptoms)
Time frame: 24 months
EORTC Sexual Health Questionnaire (SHQ22) (0-100, higher scores indicate better quality of life or more symptoms)
Contact information is provided by the study sponsor or research team.
Belle de Rooij, PhD
CONTACT
Nicole Ezendam, PhD
CONTACT
Comprehensive Cancer Centre The Netherlands
Other
Mechanisms Explaining Psychological Distress In CErvical Cancer Patients and Partners (DICE): a Population-based Prospective Study
Acronym: DICE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04512144
Cervical Cancer, Endometrial Cancer
St Louis, Missouri, United States
View Trial DetailsNCT05035173
Breast Cancer, Breast Diseases
Cork, Ireland
View Trial DetailsNCT04165460
Anxiety Disorders, Behavior
Mexico City, Tlalpan, Mexico
View Trial DetailsNCT02642471
Cervical Cancer, Female Urogenital Diseases
Guangzhou, Guangdong, China
View Trial Details